Stock SGMT SAGIMET BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sagimet Biosciences Inc.

Equities

SGMT

US7867001049

End-of-day quote Nasdaq
Other stock markets
 18:00:00 2024-06-04 EDT 		5-day change 1st Jan Change
4.64 USD -7.57% Intraday chart for Sagimet Biosciences Inc. -15.17% -14.39%
02:07pm Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data MT
11:00am Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024
GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
AQ
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GL
Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
AQ
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
GL
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
GL
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
GL
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
AQ
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
GL
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
GL
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
AQ
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
GL
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
GL
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
GL
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
AQ
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMT Stock
  4. News Sagimet Biosciences Inc.
  5. Press Releases